Karyopharm Therapeutics has entered a restructuring agreement that calls for Ayrmid Ltd. to merge with a reorganized Karyopharm, while the cancer-drug maker moves through Chapter 11 bankruptcy. Ayrmid will serve as the lead bidder in a court-supervised sale process, which will allow other parties to submit competing offers.
Karyopharm expects the transaction to close in the first quarter of 2027, subject to court approval and other conditions. The company says its existing common stock and convertible preferred stock are expected to receive no recovery.
Key details
-
Ayrmid’s proposal is not yet a guaranteed outcome. The agreement with Karyopharm’s lenders, noteholders and other key stakeholders provides for a merger with Ayrmid. But Karyopharm plans to seek court approval for bidding procedures that would let other parties make competing proposals for its assets.
-
Karyopharm has filed for Chapter 11. The company expects to carry out the transaction through a bankruptcy reorganization plan. It is targeting completion in the first quarter of 2027, subject to the plan’s conditions and court approval.
-
The company has secured a commitment for up to $55 million in additional financing. Existing secured lenders have committed to provide debtor-in-possession financing, which requires court approval. Karyopharm expects the financing, together with cash from ongoing operations, to support the business and help meet obligations during the bankruptcy process.
-
Karyopharm says operations and patient programs are expected to continue. The company plans to operate in the ordinary course while in Chapter 11 and says it expects no disruption to its operations or partnerships. It says it remains focused on its multiple myeloma and myelofibrosis programs.
-
The proposed combination is framed as a hematology-focused business. Ayrmid says the companies have complementary portfolios and commercial capabilities, and points to Karyopharm’s marketed products, development pipeline and team as assets it hopes to build on.
What it means for current shareholders
Karyopharm says its plan provides for holders of common stock and convertible preferred stock to receive no payment or other distribution. The company expects those securities to have no value and says their holders will suffer a complete loss. It also warns that trading prices during the bankruptcy process may not reflect any eventual recovery.